Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial
Journal of Internal Medicine · 2025-02 · 297 (2) · 141-155
DOI: 10.1111/joim.20038 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Internal Medicine, online erschienen am 26.12.2024. Verfasst von José Ignacio Martínez-Montoro und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain. Hauptthemen laut MEDLINE: Cystatin C, Obesity, Overweight, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rio Hortega, Juan Rodes JR, Fondo Europeo de Desarrollo Regional-FEDER.
Abstract (Originalsprache)
Background
Large‐scale trials evaluating a multicomponent lifestyle intervention aimed at weight loss on kidney function are lacking.
Methods
This was a post hoc analysis of the “PREvención con DIeta MEDiterránea‐Plus” (PREDIMED‐Plus) randomized controlled trial, including patients with overweight/obesity and metabolic syndrome, measured cystatin C and creatinine. Participants were randomly assigned (1:1) to an intensive weight loss lifestyle intervention (intervention group [IG]) consisting of an energy‐restricted Mediterranean diet (MedDiet), physical activity promotion and behavioral support, or a control group (CG) receiving ad libitum MedDiet recommendations. The primary outcome was between‐group differences in cystatin C–based kidney function (cystatin C–based estimated glomerular filtration rate—eGFRcys—and combined cystatin C–creatinine‐based eGFR—eGFRcr‐cys) change from baseline to 12 and 36 months. Secondary outcomes included between‐group differences in creatinine‐based eGFR (eGFRcr) and urinary albumin‐to‐creatinine ratio (UACR) change and the predictive capacity of these formulas at baseline for new‐onset chronic kidney disease (CKD).
Results
A total of 1909 participants (65 ± 5 years, 54% men) were included. Twelve‐month decline in eGFRcys, eGFRcr‐cys, and eGFRcr was greater in the CG compared to the IG, with between‐group differences of −1.77 mL/min/1.73 m 2 [95% confidence interval −2.92 to −0.63], −1.37 [−2.22 to −0.53], and −0.91 [−1.74 to −0.71], respectively. At 36 months, the decline in eGFRcr‐cys and eGFRcr was greater in the CG. No between‐group differences in UACR were found. Significant adjusted areas under the curve for baseline eGFRcys and eGFRcr‐cys were observed for incident CKD at 36 months, which were similar to those for eGFRcr and UACR.
Conclusions
In older adults with overweight/obesity and metabolic syndrome, the PREDIMED‐Plus intervention may be an optimal approach to preserve kidney function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, Málaga, Spain.
- Instituto de Investigación Biomédica de Málaga (IBIMA)-Plataforma BIONAND, Málaga, Spain.
- Faculty of Medicine, University of Málaga, Málaga, Spain.
- Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBERObn: Physiopathology of Obesity and Nutrition, CB12/03/30038), Instituto de Salud Carlos III, Madrid, Spain.
- Nutrition and Mental Health (NUTRISAM) Research Group, Universitat Rovira i Virgili (URV), Reus, Spain.
- Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
ORCID-Profile: José Ignacio Martínez-Montoro, Isabel Cornejo-Pareja
Förderung
- Rio Hortega
- Juan Rodes JR
- Fondo Europeo de Desarrollo Regional-FEDER
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN)
- European Regional Development Fund
- Instituto de Salud Carlos III
Zitieren
APA
Martínez-Montoro, J. I., Cornejo-Pareja, I., Díaz-López, A., Sureda, A., Toledo, E., Abete, I., Babio, N., Tur, J. A., Martinez-Gonzalez, M. A., Martínez, J. A., Fitó, M., Salas-Salvadó, J., Tinahones, F. J., & PREDIMED‐Plus Investigators (2025). Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial. Journal of Internal Medicine, 297(2), 141-155. https://doi.org/10.1111/joim.20038
Vancouver
Martínez-Montoro JI, Cornejo-Pareja I, Díaz-López A, Sureda A, Toledo E, Abete I, et al. Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial. Journal of Internal Medicine. 2025;297(2):141-155. doi:10.1111/joim.20038
BibTeX
@article{MartnezMontoro2025,
author = {Martínez-Montoro, José Ignacio and Cornejo-Pareja, Isabel and Díaz-López, Andrés and Sureda, Antoni and Toledo, Estefania and Abete, Itziar and Babio, Nancy and Tur, Josep A and Martinez-Gonzalez, Miguel A and Martínez, J Alfredo and Fitó, Montse and Salas-Salvadó, Jordi and Tinahones, Francisco J and PREDIMED‐Plus Investigators, PREDIMED‐Plus Investigators},
title = {Effect of an intensive lifestyle intervention on cystatin C–based kidney function in adults with overweight and obesity: From the PREDIMED‐Plus trial},
journal = {Journal of Internal Medicine},
year = {2025},
volume = {297},
number = {2},
pages = {141--155},
doi = {10.1111/joim.20038}
}
EUVIMED